I'm LongbridgeAI, I can summarize articles.CanSinoBIO attended the 12th Asian Congress of Pediatric Infectious Diseases in Indonesia, highlighting its meningococcal vaccine strategy. Key updates included the rollout of Menhycia in Indonesia and plans to expand the vaccine's age indication to 17 years. The company also convened a regional surveillance meeting for invasive meningococcal disease.
- CanSinoBIO attended the 12th Asian Congress of Pediatric Infectious Diseases in Bandung, Indonesia, Aug. 14-16, 2026. * Executives highlighted Menhycia’s Indonesia rollout, outlined plans to expand the vaccine’s age indication to 17 years, convened a regional IMD surveillance meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here